Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of “Moderate Buy” by Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC) has been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $3.80.

Several research analysts recently weighed in on IPSC shares. TD Cowen assumed coverage on shares of Century Therapeutics in a research note on Wednesday, February 25th. They issued a “buy” rating for the company. Leerink Partners downgraded shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 17th. Wall Street Zen raised shares of Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Research raised shares of Century Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 6th. Finally, Piper Sandler upped their price objective on shares of Century Therapeutics from $2.00 to $4.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th.

Insider Buying and Selling at Century Therapeutics

In other Century Therapeutics news, CEO Brent Pfeiffenberger purchased 52,000 shares of the business’s stock in a transaction on Friday, December 12th. The stock was bought at an average cost of $0.58 per share, for a total transaction of $30,160.00. Following the acquisition, the chief executive officer owned 3,322,990 shares of the company’s stock, valued at approximately $1,927,334.20. The trade was a 1.59% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Chad Cowan purchased 58,060 shares of Century Therapeutics stock in a transaction on Monday, December 22nd. The shares were acquired at an average cost of $0.85 per share, for a total transaction of $49,351.00. Following the purchase, the insider owned 1,045,087 shares in the company, valued at approximately $888,323.95. This trade represents a 5.88% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 1,106 shares of company stock valued at $1,003 over the last quarter. 4.37% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of IPSC. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Century Therapeutics in the fourth quarter worth approximately $1,829,000. Spruce Street Capital LP acquired a new position in Century Therapeutics during the fourth quarter worth approximately $1,414,000. Jane Street Group LLC purchased a new position in Century Therapeutics during the second quarter worth approximately $248,000. Two Sigma Investments LP raised its stake in Century Therapeutics by 59.2% during the third quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock worth $454,000 after purchasing an additional 338,902 shares during the period. Finally, Squarepoint Ops LLC boosted its holdings in shares of Century Therapeutics by 483.1% in the 3rd quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock valued at $118,000 after purchasing an additional 195,573 shares during the last quarter. 50.20% of the stock is currently owned by hedge funds and other institutional investors.

Century Therapeutics Price Performance

Shares of Century Therapeutics stock opened at $2.56 on Monday. Century Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.71. The company has a market capitalization of $223.74 million, a P/E ratio of -8.00 and a beta of 1.70. The business has a 50 day moving average price of $1.92 and a 200 day moving average price of $1.04.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.